WUXI APPTEC - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We are not responsible for any losses caused by reliance on such content.

WUXI APPTEC CO., LTD.* Wuxi WuXi AppTec New Drug Development Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China) (Stock code: 2359)

Overseas Regulatory Announcements

This overseas regulatory announcement is made by the Company in accordance with Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

Section 13.10B is made.

The full Chinese text of the following information published by the Company on the Shanghai Stock Exchange website is hereby provided for reference only.

By order of the board of directors Wuxi WuXi AppTec New Drug Development Co., Ltd. Chairman

Dr. Li Ge

Hong Kong, March 23, 2026

As of the date of this announcement, the Company's Board of Directors includes executive directors Dr. Li Ge, Dr. Chen Minzhang, Dr. Yang Qing and Mr. Zhang Zhaohui; Non-executive directors Mr. Tong Xiaoyi and Dr. Wu Yibing; and independent non-executive directors Ms. Lu Shaohua, Dr. Yu Wei, Dr. Zhang Xin, Ms. Zhan Zhiling and Mr. Leng Xuesong.

*For identification only

Securities code: 603259 Securities abbreviation: WuXi AppTec Announcement number: Lin 2026-010

Wuxi WuXi AppTec New Drug Development Co., Ltd.

Announcement on Provision for Asset Impairment in 2025

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements. or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its content.

1. Provision for impairment losses in 2025

In accordance with the "Accounting Standards for Business Enterprises" and relevant accounting policies, in order to truly and accurately reflect Wuxi Pharmaceutical Mingkangde New Drug Development Co., Ltd. (hereinafter referred to as the "Company") as of December 31, 2025

financial status and operating results in 2025, the company conducted an inventory of relevant assets within the scope of consolidation, and based on

Based on the principle of prudence, impairment provisions have been made for related assets that may suffer impairment losses. The specific situation is as follows

The table shows:

In 2025, the company accrued credit impairment losses and asset impairment losses totaling RMB 1,069.518 million.

Among them, credit impairment losses were RMB 527.962 million and asset impairment losses were RMB 541.556 million.

2. Explanation of impairment losses in 2025

(1) Credit impairment losses and contract asset impairment losses

In accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments", the company

Bad debt provisions are made for accounts receivable and contract assets based on a combination of credit risk characteristics. In 2025, the company

Credit impairment losses of RMB 527.962 million were accrued on accounts receivable, and contract asset impairment losses were accrued on contract assets.

Lost 143.9012 million yuan.

(2) Loss from inventory depreciation

According to the provisions of "Accounting Standards for Business Enterprises No. 1 - Inventory", the inventory on the balance sheet date is calculated as cost.

The lower of the cost and net realizable value is measured. When the inventory cost is higher than its net realizable value, inventory depreciation losses are accrued.

In 2025, the company accrued a loss of RMB 42.3852 million for inventory depreciation.

(3) Impairment losses on fixed assets/projects under construction/intangible assets/other long-term assets

According to the "Accounting Standards for Business Enterprises No. 8 - Asset Impairment", the company shall review the assets and liabilities on each balance sheet date.

Check whether there are other long-term assets such as fixed assets, projects under construction, intangible assets with definite useful lives, etc.

Indications of impairment. If there is any indication of impairment of these assets, estimate their recoverable amount. If the asset

If the recoverable amount is lower than its book value, asset impairment provisions will be made based on the difference and included in the current profit and loss. In 2025, the company will make provision for impairment of fixed assets, projects under construction, intangible assets and other long-term assets respectively.

The losses were RMB 112,821,100, RMB 108,403,900, RMB 658,400, and RMB 12,649,100.

(4) Impairment losses on assets held for sale

According to Accounting Standards for Business Enterprises No. 42 - Non-current assets held for sale, disposal groups and termination

Operations", the company measures the assets held for sale at the lower of the book value and the fair value minus selling expenses.

Non-current assets or disposal groups. If the book value is higher than the fair value minus selling expenses, the book value will be reduced. The net amount from face value to fair value minus selling expenses is recognized as asset impairment loss.

In 2025, the company accrued impairment losses of RMB 120.7372 million on assets held for sale.

3. The impact of this recognition of impairment losses on the company

The provision of credit impairment losses and asset impairment provisions at the end of the year involves a number of factors that require the auditor's professional judgment and confirmation.

For matters recognized, the relevant amounts must be confirmed item by item after the annual audit is completed. After audit, the company in 2025

A total of 1,069.518 million yuan has been provided for various impairment losses, which will reduce the company's total consolidated statement profit in 2025. The amount is 1,069.518 million yuan. The above provision for impairment losses complies with the relevant provisions of the Accounting Standards for Business Enterprises and can

truly and objectively reflect the company’s financial status as of December 31, 2025 and operating results for 2025

As a result, it complies with the provisions of relevant laws and regulations and the actual situation of the company, and will not affect the company's normal operations. There is no

Situations that harm the interests of the company and all shareholders.

Announcement is hereby made.

Board of Directors of Wuxi WuXi AppTec New Drug Development Co., Ltd.

March 24, 2026